Bioinformatics firm Ariadne, US, has announced a new collaboration with the BIO-NMD consortium led by Professor Alessandra Ferlini at the University of Ferrara, Italy. BIO-NMD is a three year EU-funded research project concentrating on the search for non-invasive biomarkers in people with Duchenne and Becker muscular dystrophies and Collagen VI myopathies. The consortium, along with leading European academic and industry partners, will work to identify non-invasive biomarkers for monitoring neuromuscular diseases (NMDs).
Utilising a myriad of OMIC sciences (genomic, transcriptomic, proteomic) and bioinformatics, the consortium hopes to bring qualified biomarkers for ongoing and further clinical trials. Ariadne's focus will be on providing bioinformatics tools for identifying functional pathways, potential targets and data outflow integration. The team will use its software, Pathway Studio, as a core to integrate the data and information flow, in addition to using its expertise in information extraction to develop a literature-derived NMD biological knowledgebase of related processes and diseases. Specifically, Ariadne will build mechanistic models and pathways for NMD and interpret OMIC data generated by the consortium and partners in the context of NMD knowledgebase and networks.
The first update workshops for the BIO-NMD consortium will be held later this month and will include sessions dedicated to its industrial partners. The consortium will present and describe the project impacts, possible outcomes and identify links for future collaborations with industry.
Search for more reference tools
